- Home
- PMAX vs XBIO Comparison
PMAX vs XBIO Comparison
Compare PMAX & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMAX
- XBIO
- Stock Information
- Founded
- PMAX 2019
- XBIO N/A
- Country
- PMAX Hong Kong
- XBIO United States
- Employees
- PMAX N/A
- XBIO N/A
- Industry
- PMAX
- XBIO Biotechnology: Pharmaceutical Preparations
- Sector
- PMAX
- XBIO Health Care
- Exchange
- PMAX Nasdaq
- XBIO Nasdaq
- Market Cap
- PMAX 4.7M
- XBIO 4.2M
- IPO Year
- PMAX 2024
- XBIO N/A
- Fundamental
- Price
- PMAX $0.34
- XBIO $2.91
- Analyst Decision
- PMAX
- XBIO Hold
- Analyst Count
- PMAX 0
- XBIO 1
- Target Price
- PMAX N/A
- XBIO N/A
- AVG Volume (30 Days)
- PMAX 1.6M
- XBIO 9.5K
- Earning Date
- PMAX 04-28-2025
- XBIO 05-13-2025
- Dividend Yield
- PMAX N/A
- XBIO N/A
- EPS Growth
- PMAX N/A
- XBIO N/A
- EPS
- PMAX N/A
- XBIO N/A
- Revenue
- PMAX $4,694,079.00
- XBIO $2,582,728.00
- Revenue This Year
- PMAX N/A
- XBIO $14.23
- Revenue Next Year
- PMAX N/A
- XBIO N/A
- P/E Ratio
- PMAX N/A
- XBIO N/A
- Revenue Growth
- PMAX N/A
- XBIO 5.63
- 52 Week Low
- PMAX $0.28
- XBIO $2.20
- 52 Week High
- PMAX $4.70
- XBIO $5.20
- Technical
- Relative Strength Index (RSI)
- PMAX N/A
- XBIO 49.56
- Support Level
- PMAX N/A
- XBIO $2.78
- Resistance Level
- PMAX N/A
- XBIO $3.22
- Average True Range (ATR)
- PMAX 0.00
- XBIO 0.24
- MACD
- PMAX 0.00
- XBIO 0.03
- Stochastic Oscillator
- PMAX 0.00
- XBIO 34.16
About PMAX Powell Max Limited Class A Ordinary Shares
Powell Max Ltd is an financial communications services provider. Its financial communications services cover a full range of financial printing, corporate reporting, communications and language support services from inception to completion, including typesetting, proofreading, translation, design, printing, electronic reporting, newspaper placement and distribution. It operates in a single business segment which is the provision of corporate financial communications and financial printing services. Key revenue is derived from Hong Kong.
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.